An Update on Canine Adenovirus Type 2 and Its Vectors
Author Information
Author(s): Bru Thierry, Salinas Sara, Kremer Eric J.
Primary Institution: Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535
Hypothesis
Vectors derived from nonhuman adenoviruses would be more clinically useful than those from human adenoviruses due to the potential lack of immunological memory.
Conclusion
Canine adenovirus type 2 (CAV-2) vectors show promise for gene transfer in the central nervous system and may be useful for treating neurodegenerative diseases.
Supporting Evidence
- CAV-2 vectors preferentially transduce neurons and have high levels of retrograde transport.
- CAV-2 has not been known to cross the species barrier and is unable to replicate in human cells.
- Pre-existing immunity to human adenoviruses limits the efficacy of human-derived vectors.
Takeaway
Scientists are studying a virus from dogs that can help deliver genes to brain cells, which might help treat diseases like Parkinson's.
Methodology
The review summarizes the biology of CAV-2 and its potential applications in gene therapy, particularly for neurodegenerative diseases.
Limitations
The clinical use of CAV-2 vectors may be limited by pre-existing immunity in humans and the need for specialized techniques for delivery.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website